ICON: Diagnosis and management of allergic conjunctivitis
- PMID: 31759180
- DOI: 10.1016/j.anai.2019.11.014
ICON: Diagnosis and management of allergic conjunctivitis
Abstract
Ocular allergy (OA), interchangeably known as allergic conjunctivitis, is a common immunological hypersensitivity disorder affecting up to 40% of the population. Ocular allergy has been increasing in frequency, with symptoms of itching, redness, and swelling that significantly impacts an individual's quality of life (QOL). Ocular allergy is an often underdiagnosed and undertreated health problem, because only 10% of patients with OA symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary nonpharmacological remedies. The clinical course, duration, severity, and co-morbidities are varied and depend, in part, on the specific ocular tissues that are affected and on immunologic mechanism(s) involved, both local and systemic. It is frequently associated with allergic rhinitis (commonly recognized as allergic rhino conjunctivitis), and with other allergic comorbidities. The predominance of self-management increases the risk of suboptimal therapy that leads to recurrent exacerbations and the potential for development of more chronic conditions that can lead to corneal complications and interference with the visual axis. Multiple, often co-existing causes are seen, and a broad differential diagnosis for OA, increasing the difficulty of arriving at the correct diagnosis(es). Ocular allergy commonly overlaps with other anterior ocular disease disorders, including infectious disorders and dry eye syndromes. Therefore, successful management includes overcoming the challenges of underdiagnosis and even misdiagnosis by a better understanding of the subtleties of an in-depth patient history, ophthalmologic examination techniques, and diagnostic procedures, which are of paramount importance in making an accurate diagnosis of OA. Appropriate cross-referral between specialists (allergists and eyecare specialists) would maximize patient care and outcomes. This would significantly improve OA management and overcome the unmet needs in global health.
Copyright © 2019. Published by Elsevier Inc.
Similar articles
-
Diagnosing and managing allergic conjunctivitis in childhood: The allergist's perspective.Pediatr Allergy Immunol. 2019 Jun;30(4):405-414. doi: 10.1111/pai.13035. Pediatr Allergy Immunol. 2019. PMID: 30742722 Review.
-
[Allergic conjunctivitis: diagnosis and treatment].Eur Ann Allergy Clin Immunol. 2004 Jan;36(1):25-9. Eur Ann Allergy Clin Immunol. 2004. PMID: 15015749 Review. French.
-
Epidemiology of allergic conjunctivitis.Curr Opin Allergy Clin Immunol. 2011 Oct;11(5):471-6. doi: 10.1097/ACI.0b013e32834a9676. Curr Opin Allergy Clin Immunol. 2011. PMID: 21785348 Review.
-
Management of ocular allergy.Ann Allergy Asthma Immunol. 1995 Sep;75(3):212-22; quiz 223-4. Ann Allergy Asthma Immunol. 1995. PMID: 7552922 Review.
-
Allergic conjunctivitis: a cross-sectional study.Clin Exp Allergy. 2015 Jun;45(6):1118-25. doi: 10.1111/cea.12536. Clin Exp Allergy. 2015. PMID: 25809830
Cited by
-
Using the Internet Big Data to Investigate the Epidemiological Characteristics of Allergic Rhinitis and Allergic Conjunctivitis.Risk Manag Healthc Policy. 2021 May 6;14:1833-1841. doi: 10.2147/RMHP.S307247. eCollection 2021. Risk Manag Healthc Policy. 2021. PMID: 33986620 Free PMC article.
-
Effects of rAmb a 1-Loaded PLGA-PEG Nanoparticles in a Murine Model of Allergic Conjunctivitis.Molecules. 2022 Jan 18;27(3):598. doi: 10.3390/molecules27030598. Molecules. 2022. PMID: 35163859 Free PMC article.
-
Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study.Postepy Dermatol Alergol. 2023 Apr;40(2):326-330. doi: 10.5114/ada.2023.127647. Epub 2023 May 31. Postepy Dermatol Alergol. 2023. PMID: 37312902 Free PMC article.
-
Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.ACS Pharmacol Transl Sci. 2020 Nov 5;3(6):1391-1421. doi: 10.1021/acsptsci.0c00137. eCollection 2020 Dec 11. ACS Pharmacol Transl Sci. 2020. PMID: 33344909 Free PMC article.
-
Immunomodulatory Actions of Cannabinoids: Clinical Correlates and Therapeutic Opportunities for Allergic Inflammation.J Allergy Clin Immunol Pract. 2023 Feb;11(2):449-457. doi: 10.1016/j.jaip.2022.10.009. Epub 2022 Oct 22. J Allergy Clin Immunol Pract. 2023. PMID: 36280137 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources